Skip to main content
micro-community-banner
 
Profile Image
  • Saved

made a Post

Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia

ABSTRACT Graft-versus-host disease (GvHD) remains a significant impediment to allogeneic hematopoietic cell transplantation (HCT) success, necessitating studies focused on alleviating GvHD, while preserving the graft-versus-leukemia (GvL) effect. see more

Source : https://doi.org/10.1080/2162402X.2020.1758011

  • Saved

Commented on 's Post

Case study: 59-year old female with history of GBM

History of present illness: A 59-year-old female presents for routine follow-up, noting nose bleeds, fatigue, chronic headaches, and ..... see more

  • Saved

made a Post

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines

Background: Multiple myeloma (MM) remains incurable despite significant advances in chemotherapy, targeted therapies, and immunotherapy. Bispecific antibody (BiAb)-armed activated T cells (BATs) have been developed for targeting and treatment of ..... see more

Source : https://doi.org/10.3389/fonc.2020.00544

  • Saved

made a Post

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer

ABSTRACT Despite some of the oncogenic driver mutations that have been associated with increased expression of programmed death-ligand 1 (PD-L1), the correlation between PD-L1 expression and ROS1 fusion in NSCLC ..... see more

Source : https://doi.org/10.1080/2162402X.2020.1758003

  • Saved

made a Post

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities

Immunotherapy has recently emerged as a promising treatment option for multiple myeloma (MM) patients. Profound immune dysfunction and evasion of immune surveillance are known to characterize MM evolution and disease ..... see more

Source : https://doi.org/10.3389/fonc.2020.00636

  • Saved

made a Post

COVID-19: a challenge for oncology services

On March 11, 2020, the WHO declared that the cluster of pneumonia cases caused by the novel coronavirus SARS-CoV-2 (COVID-19) from Wuhan, China was a global pandemic. 1 As of ..... see more

Source : https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1760686

  • Saved

made a Post

The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma

As the global population is aging and survival in multiple myeloma (MM) is increasing, treating older MM patients, redefined as non-transplant eligible (NTE), is becoming more frequent. Yet, treating these ..... see more

Source : https://doi.org/10.3389/fonc.2020.00676

  • Saved

made a Post

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities

Immunotherapy has recently emerged as a promising treatment option for multiple myeloma (MM) patients. Profound immune dysfunction and evasion of immune surveillance are known to characterize MM evolution and disease ..... see more

Source : https://doi.org/10.3389/fonc.2020.00636

  • Saved

made a Post

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort

Background The biological underpinnings of the prognostic and predictive significance of a relative neutrophilia in patients with non-small lung cancer (NSCLC) are undefined. We sought to comprehensively examine the relationships ..... see more

Source : https://jitc.bmj.com/content/8/1/e000405

  • Saved

made a Post

Development of CAR-T cell therapy for B-ALL using a point-of-care approach

ABSTRACT Recently approved by the FDA and European Medicines Agency, CAR-T cell therapy is a new treatment option for B-cell malignancies. Currently, CAR-T cells are manufactured in centralized facilities and ..... see more

Source : https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1752592

  • Saved

Commented on 's Post

Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1+ Myeloma Cells and Release Type-1 Cytokines

Background: Multiple myeloma (MM) remains incurable despite significant advances in chemotherapy, targeted therapies, and immunotherapy. Bispecific antibody (BiAb)-armed activated T cells (BATs) have been developed for targeting and treatment of ..... see more

Source : https://www.frontiersin.org/articles/10.3389/fonc.2020.00544/full

  • Saved

made a Post


Daratumumab Subcutaneous FDA APPROVED (Darzelex FASPRO)!
I literally just posted (10 minutes ago!) comments on the recent approval of isatuximab (Sarclisa) in combination with pomalidomide and dexamethasone for the ..... see more

  • Saved

made a Post

On March 2, 2020, the FDA approved isatuximab (Sarclisa) in combination with pomalidomide and dexamethasone for multiple myeloma patients with relapsed or refractory disease after at least two prior therapies. ..... see more

  • Saved

made a Post

Prognostic Value of Tumor-Infiltrating Lymphocytes Differs Depending on Lymphocyte Subsets in Esophageal Squamous Cell Carcinoma: An Updated Meta-Analysis

Background: Tumor-infiltrating lymphocytes (TILs) play a role in the anti-tumor immune response, and are often found in esophageal squamous cell carcinoma (ESCC).Methods: We performed a systematic review and meta-analysis, aiming ..... see more

Source : https://doi.org/10.3389/fonc.2020.00614

  • Saved

made a Post

CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models

ABSTRACT In our previous studies, using a B cell vaccine (scFv-Her2), the targeting of tumor-associated antigen Her2 (human epidermal growth factor receptor-2) to B cells via the anti-CD19 single chain ..... see more

Source : https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1747688

  • Saved

made a Post

Prognostic value of CD73 expression in resected colorectal cancer liver metastasis

ABSTRACT ABSTRACT Immune checkpoint blockade has not yet been effective in patients with mismatch repair proficient metastatic colorectal cancer. Targeting immunosuppressive metabolic pathways is being explored as a new immunotherapeutic ..... see more

Source : https://doi.org/10.1080/2162402X.2020.1746138

  • Saved

made a Post

Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors

Immunotherapy has revolutionized the treatment of both hematological malignancies and solid tumors. The use of immunotherapy has improved outcome for patients with cancer across multiple tumor types, including lung, melanoma, ..... see more

Source : https://doi.org/10.3389/fonc.2020.00570

  • Saved

made a Post

Staphylococcus aureus alpha-toxin inhibits CD8 T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma

ABSTRACT ABSTRACT Staphylococcus aureus and its toxins have been linked to disease progression and mortality in advanced stages of cutaneous T-cell lymphoma (CTCL). CD8 T cells play a crucial ..... see more

Source : https://doi.org/10.1080/2162402X.2020.1751561

  • Saved

made a Post

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of ..... see more

Source : https://jitc.bmj.com/content/8/1/e000878?int_source=wisepops&int_medium=wisepops&int_campaign=usage

  • Saved

made a Post

FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer

Background: Colorectal cancer (CRC) is the third most common malignancy worldwide. The presence of CD8 tumor-infiltrating T lymphocytes (TILs) is associated with improved prognosis and therapeutic response in CRC patients. ..... see more

Source : https://doi.org/10.3389/fonc.2020.00586